5 Quotes by Benjamin Andrew

Getting European Commission approval is a key step ... but the fact that there has been such a disconnect between the takeout price of $76 (per Guidant share) and the current share price tells you there's more uncertainty and nervousness out there than normal.

I think the company in general is in very good shape, but there are some general investor concerns about how long Stryker can maintain its 20-plus percent growth in earnings operational rate.

Early on, treating (sleep apnea) was largely a lifestyle issue because people were falling asleep in the day and this would help them feel better.

If you don't invest in R&D, you're going to get left behind, because all the other companies are doing it.

All the while the company's done a good job of maintaining strong gross margins in a tough reimbursement market like the U.S.. That means they're controlling costs well on the manufacturing side, which isn't an easy thing to do.